These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24219367)

  • 1. Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period.
    Tran DH; Wong GT; Chee YE; Irwin MG
    Expert Opin Biol Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24219367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for treatment of anemia of chronic kidney disease.
    Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.
    Robles NR
    Clin Drug Investig; 2016 Jun; 36(6):421-31. PubMed ID: 26894799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S; Littlewood TJ
    Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood conservation strategies in major orthopaedic surgery: efficacy, safety and European regulations.
    Muñoz M; García-Erce JA; Villar I; Thomas D
    Vox Sang; 2009 Jan; 96(1):1-13. PubMed ID: 19121192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for the Management of Postoperative Anemia in Elective Orthopedic Surgery.
    Steuber TD; Howard ML; Nisly SA
    Ann Pharmacother; 2016 Jul; 50(7):578-85. PubMed ID: 27147703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation.
    Martino M; Lanza F; Demirer T; Moscato T; Secondino S; Pedrazzoli P;
    Expert Opin Biol Ther; 2015 Feb; 15(2):195-211. PubMed ID: 25315815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.
    Duh MS; Weiner JR; White LA; Lefebvre P; Greenberg PE
    Pharmacoeconomics; 2008; 26(2):99-120. PubMed ID: 18198931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
    Agarwal R
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents.
    Geisler BP
    Expert Opin Biol Ther; 2010 Aug; 10(8):1209-16. PubMed ID: 20557272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
    Bennett CL; Silver SM; Djulbegovic B; Samaras AT; Blau CA; Gleason KJ; Barnato SE; Elverman KM; Courtney DM; McKoy JM; Edwards BJ; Tigue CC; Raisch DW; Yarnold PR; Dorr DA; Kuzel TM; Tallman MS; Trifilio SM; West DP; Lai SY; Henke M
    JAMA; 2008 Feb; 299(8):914-24. PubMed ID: 18314434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future chemical therapies for treating anaemia in chronic kidney disease.
    Locatelli F; Del Vecchio L; Luise MC
    Expert Opin Pharmacother; 2017 Jun; 18(8):781-788. PubMed ID: 28443351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietic stimulating agents.
    Testa U
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):119-38. PubMed ID: 20158404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
    Rainville N; Jachimowicz E; Wojchowski DM
    Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: a meta-analysis of randomized clinical trials.
    Alsaleh K; Alotaibi GS; Almodaimegh HS; Aleem AA; Kouroukis CT
    J Arthroplasty; 2013 Oct; 28(9):1463-72. PubMed ID: 23528548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.